LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy

Atherosclerosis

Volumn 225, Issue 1, 2012, Pages 200-207

  Saumoy, Maria ^a   Sánchez Quesada, José Luis ^b   Martínez, Esteban ^c   Llibre, Josep Maria ^d   Ribera, Esteban ^e   Knobel, Hernando ^f   Gatell, Josep Maria ^c   Clotet, Bonaventura ^d   Curran, Adrian ^e   Curto, Jordi ^a   Masó, Margarita ^a   Ordoñez Llanos, Jordi ^b   Podzamczer, Daniel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL DEL MAR   (Spain)

Author keywords

LDL phenotype; LDL size; Lipoprotein associated phospholipase A2; Raltegravir; Ritonavir boosted protease inhibitor

Indexed keywords

ABACAVIR; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATAZANAVIR; CHOLESTEROL; EMTRICITABINE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; KEXIN TYPE 9; LAMIVUDINE; LIPOPROTEIN; LOPINAVIR; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; RALTEGRAVIR; SUBTILISIN; TENOFOVIR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; VIROTHERAPY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; CHOLESTEROL, LDL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRROLIDINONES;

EID: 84867881845     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.08.010     Document Type: Article

References (33)

1. Kamin D.S., Grinspoon S. Cardiovascular disease in HIV-positive patients. AIDS 2005, 19:641-652.
2. Markowitz M., Nguyen B.-Y., Gotuzzo E., et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Defic Syndr 2009, 52:350-356.
3. Rockstroh J.K., Lennox J.L., DeJesus E., et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1- infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011, 53:807-816.
4. Steigbigel R.T., Cooper D.A., Kumar P.N., et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 359:339-354.
5. Martinez E., Larrousse M., Llibre J.M., et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010, 24:1697-1707.
6. Eron J.J., Young B., Cooper D.A., et al. Switch to a raltegravir-based regimen versus continuation of lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010, 375:396-407.
7. National Cholesterol Education Program Third report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002, 106:3143-3421.
8. St-Pierre A.C., Cantin B., Dagenais G.R., et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men. 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005, 25:553-559.
9. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1554. The Lp-PLA2 Studies Collaboration.
10. Negredo E., Ribalta J., Paredes R., et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002, 16:1383-1389.
11. Badiou S., Merle De Boever C., Dupuy A.M., Baillat V., Cristol J.P., Reynes J. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?. Atherosclerosis 2003, 168:107-113.
12. Riddler S.A., Li X., Otvos J., et al. Antiretroviral therapy is associated with and atherogenic lipoprotein phenotype among HIV-1-infected men in the multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2008, 48:281-288.
13. Stein J.H., Klein M.A., Bellehumeur J.L., et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:257-262.
14. Randell P.A., Jackson A.G., Boffito M., et al. Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naïve HIV-type-1-positive men. Antivir Ther 2010, 15:1125-1132.
15. Duprez D.A., Kuller L.H., Tracy R., et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009, 207:524-529.
16. Tien P.C., Schneider M.F., Cox C., et al. HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study. AIDS 2010, 24:2809-2817.
17. Khovidhunkit W., Memon R.A., Shigenaga J.K., et al. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1999, 48:1524-1531.
18. Saumoy M., Ordoñez-Llanos J., Martínez E., et al. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in virologically suppressed HIV-infected patients switching to abacavir or tenofovir. Antivir Ther 2011, 16:459-468.
19. Lambert G., Sjouke B., Choque B., et al. The PSCK9 decade. J Lipid Res 2012, 17. [Epub ahead of print].
20. Wilson P.W.F., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
21. Benítez S., Sánchez-Quesada J.L., Ribas V., et al. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation 2003, 108:92-96.
22. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423. The Emerging Risk Factors Collaboration.
23. Pérez-Matute P., Pérez-Martínez L., Blanco J.R., Oteo J.A. Neutral actions of raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes. Curr HIV Res 2001, 9:174-179.
24. Gazi I.F., Tsimihodimos V., Tselepis A.D., Elisaf M., Mikhailidis D.P. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007, 7:53-72.
25. Eron J., Yeni P., Gathe J., et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006, 368:476-482.
26. Molina J.M., Andrade-Villanueva J., Echevarria J., et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE Study. J Acquir Immune Defic Syndr 2010, 53:323-332.
27. Carey D., Amin J., Boyd M., Petoumenos K., Emery S. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010, 65:1878-1888.
28. Vrouenraets S.M., Wit F.W., Fernandez Garcia E., et al. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients. HIV Med 2011, 12:620-631.
29. Tellis C.C., Tselepis A.D. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009, 1791:327-338.
30. Silva I.T., Mello A.P.Q., Damasceno N.R.T. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2): a review. Lipids Health Dis 2011, 10:170-180.
31. Gazi I., Lourida E.S., Filippatos T., et al. Lipoprotein-associatec phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005, 51:2264-2273.
32. Epps K.C., Wilensky R.L. Lp-PLA2-a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med 2011, 269:94-106.
33. Hatoum I.J., Nelson J.J., Cook N.R., Hu F.B., Rimm E.B. Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr 2010, 91:786-793.